English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Volume 6 • Issue 1 • 2014 The malignant gliomas are primary brain tumors and represents about 78% of all malignant tumors of the central nervous system [1]. The majority of these tumors are considered as high-grade tumors according to the current classification of the World Health Organization (grades III and IV) when diagnosed. Glioblastoma (GB) is the most aggressive form of gliomas, and is highly infiltrative and is morphologically very heterogeneous. Currently, the protocol adopted for the treatment of glioblastoma is based on surgery followed by radiation therapy and chemotherapy. Despite recent advances in the therapy of malignant gliomas with the introduction of new therapeutic agents as temozolomide [2] and antibody antiangiogenic therapy against thevascular endothelial growth factor (VEGF) [3] the median survivaltime for glioblastoma patients is still around 14 months [2]. Therefore, compounds that show antitumoractivity may be key allies to improve the conventionaltreatment applied to tumors of the CNS.The search for alternative drugs for therapeutic interventionsagainst brain tumors has shed light on phytochemical drugs.

Antiglioma Potential of Flavonoides